



ONE STOP SOLUTION FOR ALL CRITICAL CARE MEDICINE LEARNING

“MASTER CLASSES IN CRITICAL CARE MEDICINE”
(COMPREHENSIVE COURSE 1) (WITH 150+ TOPICS INCLUDED)

(one and only successfully running digital learning platform in critical care medicine throughout the globe)

Dear all after the huge success of previous batches of “Master Classes in Critical Care Medicine”, we are happy to announce the schedule of **COMPREHENSIVE CRITICAL CARE COURSE-1** from **February 2025**.



Features of Comprehensive Course 1

- Recorded version of the classes will be available to watch as per your convenience for the entire tenure of the course (from the start date of the course to end of the course-total 6 months) on mobile/laptop/desktop with the individual login details
- To cover theory/practical points/MCQs of entire critical care medicine topics
- 10 Mock Tests with explanation of the answers included
- Case based approach to help CTCCM/IDCCM/IFCCM, EDIC/EDIAC II and DM/DrNB exit exams
- To discuss MCQs according to new pattern of NEET-SS and INI-CET critical care super speciality entrance exam
- Round the clock, one to one doubt clarification – to help practicing intensivists / anaesthetists / physicians / pulmonologists / emergency physicians
- Continued academic support to registered delegates through “VOICE OF CRITICAL CARE MEDICINE” even after the batch is over
- With many more newer topics and MCQs included.

Who should attend ?

- Those who are practicing Critical Care Medicine, Anaesthesia, Pulmonology, General Medicine and Emergency Medicine and interested to learn and upgrade the knowledge in critical care medicine.
- Those who are doing postgraduation in Anaesthesia, Pulmonology, General Medicine and Emergency Medicine and interested to choose Critical Care as career option.
- Those who are doing CTCCM, IDCCM, IFCCM, PDCC, FNB/DNB, DM in critical care.
- Those who are preparing for EDIC/EDIAC part I & II.
- Those who are preparing for NEET super speciality and INI-CET entrance.



Scan QR Code
to register

COURSE FACULTY & DIRECTOR

Dr Harish Mallapura Maheshwarappa

MBBS, MD, DNB, IDCCM, DM (Critical Care Medicine TMH, Mumbai),
EDIC(Dublin), Fellowship in Infectious Diseases, FIARC, MBA
Intensive Care Physician and Infectious Disease Specialist

Mail : dr.harishmm@rocketmail.com

Call : +91-80952 18493

web : <https://harishcriticalcareclasses.com/>



Classes will be starting
from February 2025

For technical Queries call : +91 95381 15187

CURRICULUM

(Around 150+ topics included)

HEMODYNAMIC MONITORING

1. PRESSURE BASED INDECES / STATIC PARAMETERS-CVP, PAOP AND ARTERIAL LINE
2. CASE BASED DISCUSSION-VOLUME BASED INDECES / DYNAMIC PARAMETERS-PPV,SVV,SPV
3. CARDIAC OUTPUT MONITORING AN OVERVIEW
4. CARDIOGENIC SHOCK-CASE BASED APPROACH
5. OBSTRUCTIVE SHOCK-CASE BASED APPROACH
6. CASE BASED DISCUSSION- FLUID RESPONSIVENESS AND ADVANCED HEMODYNAMIC MONITORING:FLOW TRAC / VOLUME VIEW / PLR
7. FAST, eFAST, POCUS, BLUE PROTOCOL AND VEXUS SCORE: AN OVERVIEW
8. HYPOTENSION PREDICTION INDEX (HPI): NEW CONCEPT IN HEMODYNAMIC MONITORING
9. NEW CONCEPT IN HEMODYNAMIC MONITORING: PULSE WAVE TRANSIT TIME

INFECTIONS AND ANTI – INFECTIVES

1. SEPSIS – A CASE BASED APPROACH
2. SEPSIS GUIDELINES 2021- WHAT'S NEW?
3. EMPERIC ANTIBIOTIC APPROACH AND ANTIBIOTIC DEESCALATION IN ICU
4. COMMUNITY ACQUIRED PNEUMONIA
5. INVASIVE FUNGAL INFECTIONS – A CASE BASED APPROACH
6. NEWER ANTIBIOTICS IN THE PIPELINE
7. MDR GRAM NEGATIVES IN ICU: BASICS AND BEYOND
8. DIFFERENTIAL USAGE OF CARBAPENAMS: CURRENT EVIDENCE
9. APPROACH TO TROPICAL INFECTIONS IN ICU
10. PK - PD OF ANTIBIOTICS IN CRITICALLY ILL PATIENTS
11. INTERPRETATION OF CULTURE SENSITIVITY REPORT: -MIC, BPC, MPC WHAT TO SEE AT THE BEDSIDE?
12. RAPID DIAGNOSTICS AND THERAPEUTIC DRUG MONITORING IN ICU : IS IT THE FUTURE?
13. TREATING HIV PATIENT : ICU PERSPECTIVE
14. INFECTION CONTROL POLICIES IN ICU:-CARING OF LINES, DRAINS AND PIPES, BIOMEDICAL WASTE MANAGEMENT, TRANSMISSION SPECIFIC ISOLATION PRECAUTIONS

INFECTIONS AND ANTI – INFECTIVES

15. IMMUNOMODULATION IN ICU WHAT IS THE EVIDENCE:- ULINASTATIN, METHYLENE BLUE , SEPSIVAC, THYMOGIN ALPHA, INTERFERON ALPHA MARIK'S PROTOCOL
16. MANAGING COMPLICATED UTI: AN OVERVIEW
17. OXA 48 AN EMERGING THREAT: WHAT WE SHOULD KNOW?
18. PULMONARY TB IN ICU: CHALLENGES IN DIAGNOSIS AND THERAPY
19. PYREXIA OF UNKNOWN ORIGIN: A PROTOCOLIZED APPROACH
20. MANAGEMENT OF COMPLICATED SKIN-SOFT TISSUE INFECTIONS IN ICU
21. CARBAPENEM RESISTANT ENTEROBACTERIACEAE AND THE OPTIONS AVAILABLE : AN OVERVIEW (PART 1)
22. CARBAPENEM RESISTANT ENTEROBACTERIACEAE AND THE OPTIONS AVAILABLE : AN OVERVIEW (PART 2)
23. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI) AND CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI) : AN OVERVIEW
24. APPROACH TO NEW ONSET OF FEVER IN ICU

RESUSCITATION AND DERESUSCITATION

1. PCO2 GAP – PRACTICAL UTILITY AT THE BEDSIDE.
2. LACTATE IN NORMOTENSIVE PATIENTS : ITS CLINICAL RELEVANCE.
3. MICROCIRCULATORY ASSESSMENT IN ICU : WHERE WE ARE TODAY?
4. DE-RESUSCITATION IN ICU PATIENTS : WHEN AND WHICH PATIENTS TO BE INITIATED?

ARDS

1. ARDS GENERAL AND VENTILATORY ASPECTS
2. LANDMARK TRIALS IN ARDS
3. UNDERSTANDING ARDS : CASE BASED APPROACH
4. AVIPTADIL - A SYNTHETIC FORM OF VASOACTIVE INTESTINAL PEPTIDE IN ARDS: CURRENT EVIDENCE
5. WHAT IS NEW IN ARDS : UNDERSTANDING DIFFERENT PHENOTYPES
6. WHAT IS NEW IN ARDS : ADJUVANT THERAPIES

CURRICULUM

(Around 150+ topics included)

MECHANICAL VENTILATION

1. NON-INVASIVE VENTILATION: CURRENT EVIDENCE
2. HIGH FLOW NASAL CANULA: CURRENT EVIDENCE
3. BASICS OF VENTILATOR GRAPHICS
4. ADVANCED MODES OF MECHANICAL VENTILATION AN OVERVIEW
5. WEANING FAILURE AND DIFFICULTY IN WEANING
6. DIAPHRAGM PROTECTIVE VENTILATION : WHAT IT IS EXACTLY?
7. RIGHT VENTRICLE-PROTECTIVE VENTILATION : HOW TO APPROACH
8. PATIENT SELF INFLICTED LUNG INJURY : UNDERSTANDING THE NEW CONCEPT.
9. LUNG STRESS AND STRAIN IN MECHANICAL VENTILATION.

ENDOCRINE AND NUTRITION

1. DIABETIC EMERGENCIES IN ICU: DKA, HHS & HYPOGLYCEAMIA
2. APPROACH TO HYPOGLYCEMIA IN ICU : AN OVERVIEW
3. ACUTE ADRENAL INSUFFICIENCY: ICU MANAGEMENT
4. MANAGING HYPOTHYROIDISM AND MYXEDEMA COMA IN ICU: AN OVERVIEW
5. MANAGING HYPERTHYROIDISM AND THYROTOXICOSIS IN ICU: AN OVERVIEW
6. AN APPROACH TO ENTERAL NUTRITION IN ICU
7. DISEASE SPECIFIC NUTRITION
8. PHARMACO-NUTRITION
9. REFEEDING SYNDROME
10. TOTAL PARENTERAL NUTRITION: WHEN, HOW MUCH AND WHICH PATIENTS?

PREGNANCY CRITICAL CARE

1. MANAGEMENT OF CRITICALLY ILL PREGNANT PATIENT
2. LIVER DISEASES DURING PREGNANCY: ACUTE FATTY LIVER OF PREGNANCY
3. LIVER DISEASES DURING PREGNANCY: HELLP
4. LIVER DISEASES DURING PREGNANCY: INTRA HEPATIC CHOLESTASIS

NEURO CRITICAL CARE

1. SUB ARACHNOID BLEED
2. MANAGING STROKE : ICU PERSPECTIVE
3. GB SYNDROME
4. MYASTHENIA GRAVIS
5. ICU ACQUIRED WEAKNESS
6. TREATING MENINGITIS: ICU PERSPECTIVES
7. A STEPWISE APPROACH TO REFRACTORY STATUS EPILEPTICUS
8. AUTO IMMUNE ENCEPHALITIS: ICU PERSPECTIVE
9. ENCEPHALOPATHY IN ICU: METABOLIC
10. ENCEPHALOPATHY IN ICU: SEPTIC
11. TRANSCRANIAL DOPPLER AND ICP MONITORING: AN OVERVIEW
12. BRAIN DEATH DECLARATION AND ORGAN PRESERVATION
13. MANAGING HEATSTROKE IN ICU : AN OVERVIEW
14. APPROACH TO AN UNCONSCIOUS PATIENT : AN OVERVIEW

TRAUMA/BURNS

1. GENERAL VIEW ON ADVANCED TRAUMA LIFE SUPPORT (ATLS)
2. ABDOMINAL TRAUMA
3. TRAUMATIC BRAIN INJURY
4. AN EVIDENCE-BASED MANAGEMENT OF BURNS PATIENT IN ICU

TOXICOLOGY/SNAKE BITE

1. TOXICOLOGY GENERAL APPROACH
2. APPROACH TO METHEMOGLOBINEMIA IN ICU
3. APPROACH TO CARBON MONOXIDE POISONING IN ICU
4. APPROACH TO PARAQUAT POISONING : AN OVERVIEW
5. APPROACH TO RATOL POISONING (YELLOW / WHITE PHOSPHORUS) : AN OVERVIEW
6. APPROACH TO RATOL :- ALUMINIUM AND ZINC PHOSPHIDE POISONING
7. ICU MANAGEMENT OF PATIENT WITH SNAKE BITE

CURRICULUM

(Around 150+ topics included)

NEPHRO CRITICAL CARE AND CONNECTIVE TISSUE DISORDERS

1. ACUTE KIDNEY INJURY
2. PRINCIPLES OF RENAL REPLACEMENT THERAPY
3. CITRATE ANTICOAGULATION DURING CRRT: CURRENT EVIDENCE
4. RENAL RESISTIVE INDEX TO PREDICT AKI: METHODOLOGY AND EVIDENCE
5. ROLE OF EXTRACORPOREAL FILTERS (CYTOSORB, OXARIS, TORAYMYXIN AND LPS ADSORBER) IN CRITICALLY ILL PATIENTS : WHERE WE ARE TODAY?
6. DIURETICS IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
7. THERAPEUTIC PLASMA EXCHANGE IN ICU: WHAT IS THE EVIDENCE?
8. MANAGING CATASTROPHIC ANTI PHOSPHOLIPID ANTIBODY SYNDROME: ROLE OF INTENSIVIST
9. RHEUMATOLOGICAL EMERGENCIES IN ICU: AN OVERVIEW

ICU ORGANISATION/QUALITY ISSUES/END OF LIFE CARE/IMAGING

1. ICU ORGANISATION AND STRUCTURE : WHAT WE NEED TO UNDERSTAND ?
2. SCORING SYSTEM IN ICU
3. QUALITY INDICATORS IN ICU: AN OVERVIEW
4. HOW TO DO CLINICAL AUDIT IN ICU?
5. COMMUNICATION IN ICU: ITS SHORTFALLS AND HOW TO IMPROVE IT?
6. TRANSPORTING A CRITICALLY ILL PATIENT: PREPARATION AND TROUBLESHOOTING?
7. QUALITY INDICATORS IN ICU: AN OVERVIEW
8. BUNDLE CARE APPROACH IN ICU
9. END OF LIFE CARE PRINCIPLES
10. WHAT IS NEW IN END-OF-LIFE CARE POLICY – INDIAN SCENARIO?
11. HOW TO DO CRITICAL APPRAISAL OF PAPER?
12. IMAGING IN ICU
13. CRITICAL APPRAISAL OF LANDMARK TRAILS IN ICU

PRACTICAL POINTS TO REMEMBER ON VASOACTIVE AGENTS: AN INTENSIVIST PERSPECTIVE

1. AN OVERVIEW ON ADRENALINE: CURRENT EVIDENCE IN ICU
2. NORADRENALINE: CLINICAL UTILITY AND EVIDENCE
3. DOPAMINE IN ICU: WHEN, WHICH PATIENTS AND HOW MUCH?
4. DOBUTAMINE: IS IT A WONDER IONODILATOR?
5. LEVOSIMENDAN: WHERE IS TIHE PLACE AMONG CRITICALLY ILL PATIENTS?
6. CLINICAL UTILITY AND CURRENT EVIDENCE ON VASOPRESSIN
7. TERLIPRESSIN IN CRITICAL CARE UNIT: BEYOND ITS ROUTINE USE
8. ANGIOTENSIN II IN VASODILATORY SHOCK: CURRENT EVIDENCE
9. PHENYLEPHRINE: WHEN AND WHICH PATIENTS TO USE?
10. MILRINONE IN MEDICAL ICU: CURRENT EVIDENCE
11. CENTHAQUINE- A NEW MEDICATION FOR HYPOVOLEMIC SHOCK: CURRENT EVIDENCE

CURRICULUM

(Around 150+ topics included)

PRACTICAL POINTS TO REMEMBER ON ANTIBIOTICS, ANTIVIRALS AND ANTIFUNGALS: AN INTENSIVIST PERSPECTIVE

1. AN OVERVIEW ON DOXYCYCLINE, TIGECYCLINE AND MINOCYCLINE
2. AN OVERVIEW ON GLYCOPEPTIDES IN ICU: VANCOMYCIN AND TEICoplanin
3. AN OVERVIEW ON LINEZOLID
4. AN OVERVIEW ON CLINDAMYCIN
5. AN OVERVIEW ON DAPTOMYCIN
6. AN OVERVIEW ON FOSFOMYCIN USE IN ICU
7. AN OVERVIEW ON LEVONADIFLOXACIN: A NOVEL ANTI-MRSA ANTIBIOTIC
8. AN OVERVIEW ON POLYMYXINS IN ICU
9. AN OVERVIEW ON ARBEKACIN
10. AN OVERVIEW ON ROLE OF CEFTRIAXONE SULBACTAM DISODIUM EDETATE IN THE ICU
11. AN OVERVIEW ON CEFTAROLINE
12. AN OVERVIEW ON CEFTAZIDIME AVIBACTAM AND AZTREONAM AVIBACTAM
13. AN OVERVIEW ON AZTREONAM AVIBACTAM
14. AN OVERVIEW ON HIGH DOSE SULBACTAM
15. AN OVERVIEW ON ECHINOCANDINS: ANIDULAFUNGIN, MICAFUNGIN AND CASPOFUNGIN
16. AN OVERVIEW ON ERTAPENEM
17. AN OVERVIEW ON FAROPENEM
18. AN OVERVIEW ON VORICONAZOLE
19. AN OVERVIEW ON ISAVUCONAZOLE
20. AN OVERVIEW ON POSACONAZOLE
21. AN OVERVIEW ON AMPHOTERICIN -B
22. AN OVERVIEW ON ANTIVIRALS: - ACYCLOVIR
23. AN OVERVIEW ON ANTIVIRALS: - GANCICLOVIR
24. AN OVERVIEW ON ANTIVIRALS: - VALGANCYCLOVIR
25. AN OVERVIEW ON ANTIVIRALS: - FOSCARNET
26. VABORBACTUM AND ITS COMBINATIONS (MEROPENEM-VABORBACTUM): AN OVERVIEW?
27. RELEBACTAM AND ITS COMBINATIONS (IMIPENEM-RELEBACTAM): CURRENT EVIDENCE
28. CLINICAL EVIDENCE ON TANIBORBACTAM COMBINATIONS (CEFEPIME-TANIBORBACTAM)
29. CLINICAL UTILITY AND EVIDENCE ON CEFIDEROCOL
30. DALBAVANCIN: AN OVERVIEW
31. PLAZOMYCIN : AN OVERVIEW

SCAN QR CODE TO REGISTER



COURSE FACULTY & DIRECTOR

Dr Harish Mallapura Maheshwarappa

MBBS, MD, DNB, IDCCM, DM (Critical Care Medicine TMH, Mumbai),
EDIC(Dublin), Fellowship in Infectious Diseases, FIARC, MBA

Intensive Care Physician and Infectious Disease Specialist

Mail : dr.harishmm@rocketmail.com

Call : +91-80952 18493



FEE STRUCTURE

CATEGORY		25% EARLY BIRD DISCOUNT TILL 15TH FEBRUARY 2025	15% EXTENDED DISCOUNT- 16TH FEBRUARY TO 28TH FEBRUARY 2025	REGULAR WITHOUT DISCOUNT-1ST MARCH 2025 ONWARDS
INDIAN DELEGATES (INR)	Registration fee	20,000	20,000	20,000
	Discount	5,000	3,000	0
	Amount after discount	15,000	17,000	20,000
	GST 18%	2,700	3,060	3,600
	Total amount payable	17,700	20,060	23,600
FOREIGN DELEGATES (USD)	Registration fee	240	240	240
	Discount	60	36	0
	Amount after discount	180	204	240
	GST 18%	35	37	44
	Total amount payable	215	241	288

CLASSES WILL BE STARTING FROM
FEBRUARY 2025